Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is on the way. We can tell because our short person scrambled to leave for the local schoolhouse. A cloud of dust was left in her wake. As for us, we are engaging in the usual rituals — brewing cups of stimulation and foraging for interesting items. Toward that end, here are a few tidbits to help you get a jump yourself. As always, we hope you have a smashing day and do keep in touch. We appreciate the tips and insights.

President Trump had billed the meeting with pharmaceutical executives as a scolding waiting to happen, STAT tells us. The Monday gathering was intended to pressure the industry to bring drug prices “way down.” But seated across from 10 pharmaceutical executives in the Cabinet Room, his long-simmering contempt for the drug industry melted away as he referred to the group as “geniuses.” In the end, the meeting signified a remarkable shift in Trump’s view of the pharmaceutical industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.